Health Care & Life Sciences » Biotechnology | Alder BioPharmaceuticals Inc.

Alder BioPharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
18,796.00
54,705.00
-
113.00
1,619.00
2,567
Cost of Goods Sold (COGS) incl. D&A
935.00
-
751.00
1,787.00
4,620.00
2,567
Gross Income
17,861.00
-
751.00
1,674.00
3,001.00
2,567
SG&A Expense
38,622.00
45,200.00
85,578.00
157,234.00
288,003.00
284,015
EBIT
20,761.00
8,804.00
86,329.00
158,908.00
291,004.00
286,582
Unusual Expense
-
-
-
1,050.00
-
1,658
Non Operating Income/Expense
94.00
60.00
157.00
177.00
273.00
309
Pretax Income
20,613.00
8,908.00
85,470.00
156,069.00
288,236.00
296,207
Equity in Affiliates
-
-
-
185.00
643.00
222
Consolidated Net Income
20,613.00
8,908.00
85,470.00
156,254.00
288,879.00
296,429
Net Income
20,613.00
8,908.00
85,470.00
156,254.00
288,879.00
296,429
Net Income After Extraordinaries
20,613.00
8,908.00
85,470.00
156,254.00
288,879.00
296,429
Net Income Available to Common
20,613.00
8,908.00
85,470.00
156,254.00
288,879.00
331,934
EPS (Basic)
3.84
0.30
2.11
3.23
4.95
4.87
Basic Shares Outstanding
21,889.30
20,506.60
40,587.00
48,407.60
58,347.30
68,099.10
EPS (Diluted)
0.94
0.30
2.11
3.23
4.95
4.87
Diluted Shares Outstanding
21,889.30
29,427.30
40,587.00
48,407.60
58,347.30
68,099.10
EBITDA
19,826.00
9,505.00
85,578.00
157,234.00
288,003.00
284,015
Non-Operating Interest Income
54.00
44.00
702.00
1,966.00
2,495.00
8,909

About Alder BioPharmaceuticals

View Profile
Address
11804 North Creek Parkway South
Bothell Washington 98011
United States
Employees -
Website http://www.alderbio.com
Updated 07/08/2019
Alder Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, which discovers, develops, and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.